ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,07005
0,00%
Bitcoin
63.773,43
0,57%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. AbbVie Inc (ABBV)

  7. AbbVie Inc (ABBV) News

ABBV

AbbVie (ABBV)

AbbVie Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:ABBV
DatumZeitQuelleÜberschriftSymbolFirma
26/04/202413h47IH Market NewsU.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation DataNYSE:ABBVAbbVie Inc
26/04/202413h35PR Newswire (US)AbbVie Reports First-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
25/04/202414h00PR Newswire (US)New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyNYSE:ABBVAbbVie Inc
23/04/202414h00PR Newswire (US)Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsNYSE:ABBVAbbVie Inc
18/04/202414h31PR Newswire (US)Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisNYSE:ABBVAbbVie Inc
12/04/202413h30PR Newswire (US)AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
09/04/202414h00PR Newswire (US)SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to AcneNYSE:ABBVAbbVie Inc
04/04/202414h00PR Newswire (US)AbbVie to Host First-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
03/04/202414h30PR Newswire (US)Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®NYSE:ABBVAbbVie Inc
01/04/202413h50GlobeNewswire Inc.NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-YearNYSE:ABBVAbbVie Inc
26/03/202412h20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNYSE:ABBVAbbVie Inc
25/03/202416h00PR Newswire (US)Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in AestheticsNYSE:ABBVAbbVie Inc
25/03/202413h31PR Newswire (US)AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNYSE:ABBVAbbVie Inc
25/03/202413h30GlobeNewswire Inc.AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNYSE:ABBVAbbVie Inc
22/03/202420h02PR Newswire (US)U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer PatientsNYSE:ABBVAbbVie Inc
21/03/202413h00PR Newswire (US)ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024NYSE:ABBVAbbVie Inc
07/03/202414h00PR Newswire (US)AbbVie to Present at the Barclays 26th Annual Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
06/03/202414h03PR Newswire (US)AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics PortfoliosNYSE:ABBVAbbVie Inc
05/03/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
05/03/202418h09PR Newswire (Canada)Dragonfly a reçu un paiement d'étape à la suite de la prise de dose du premier patient à l'essai clinique de phase 1 d'AbbVie évaluant le DF4101/ABBV-303NYSE:ABBVAbbVie Inc
05/03/202414h00PR Newswire (US)JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA ApprovalNYSE:ABBVAbbVie Inc
05/03/202413h00PR Newswire (US)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
05/03/202413h00PR Newswire (Canada)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
05/03/202413h00PR Newswire (US)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
02/03/202401h53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
01/03/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
01/03/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
01/03/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
01/03/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
01/03/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
 Showing the most relevant articles for your search:NYSE:ABBV

Kürzlich von Ihnen besucht

TG
DBK
Deutsche Bank
TG
432
Arbor Metals
CCOM
SILVER
SILVER
FX
EURGBP
Euro vs Sterling
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
MSFT
Microsoft
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
JPM
JP Morgan Chase
AMEX
XLF
Financial Select Sector
CCOM
US30
US 30
USOTC
ADDYY
Adidas (QX)
NASDAQ
AMZN
Amazon.com
NYSE
NKE
Nike
NYSE
MCD
McDonalds
NYSE
MRK
Merck
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten